Key takeaways
- Oral Wegovy (semaglutide 25 mg tablets with SNAC, once daily) was approved December 2025 after producing about 13.6% weight loss at 64 weeks in the OASIS 4 trial, close to the 14.9% of the injection in STEP 1.
- It must be taken on an empty stomach with a small amount of water and nothing else for 30 minutes; missing that ritual reduces absorption sharply.
- Launch self-pay pricing through NovoCare was set below Wegovy pen pricing, narrowing the gap with compounded semaglutide; our database holds the figure as unverified pending re-check.
- The tablet is FDA-approved with measured bioavailability; compounded sublingual and ODT semaglutide have neither, and the oral Wegovy tablet is the only evidence-based needle-free option.
- Compounded injectable semaglutide at $119-$139 remains cheaper; the tablet wins for patients who will not inject, want an FDA-approved product, or whose insurance covers it.
A first
For four years, GLP-1 weight management meant injections. Rybelsus, the oral semaglutide approved in 2019, was a diabetes drug at doses too low for meaningful weight loss. The oral Wegovy tablet, approved in December 2025 at 25 mg once daily, is the first FDA-approved oral GLP-1 for chronic weight management, and it changes the comparison for a specific group of patients: those who will not inject, and those who want an FDA-approved product at something closer to compounded prices.
What the tablet is
The tablet co-formulates semaglutide with SNAC, an absorption enhancer that protects the peptide from gastric enzymes and transiently increases the permeability of the stomach lining. Absorption happens in the stomach, not the intestine. Bioavailability is about 1% and variable, which is why the dose is 25 mg daily against 2.4 mg weekly for the injection, and why administration is strict: first thing in the morning, empty stomach, with no more than 4 ounces of water, and nothing else for at least 30 minutes. Taking it with food, with more water, or with other medications in that window reduces absorption substantially. Patients who cannot keep the ritual get less drug.
Trial results
OASIS 4 randomized adults with obesity (or overweight with a complication) without diabetes to oral semaglutide 25 mg or placebo for 64 weeks. Mean weight loss was about 13.6% versus 2.2% — an effect close to STEP 1's 14.9% for the injection at 68 weeks. Roughly a third of participants lost 20% or more. Gastrointestinal adverse events were similar in nature and frequency to the injection, most common during titration. OASIS 1, which tested 50 mg daily, produced about 15.1% at 68 weeks; the 25 mg dose was chosen for approval as the better balance of effect and tolerability.
The tablet has not been compared head-to-head with the injection, and cross-trial comparisons have the usual caveats. The reasonable reading is that the pill delivers most of the injection's effect in patients who take it correctly.
Pricing
Novo Nordisk launched the tablet through NovoCare Pharmacy at a self-pay price below Wegovy pen pricing, as part of a broader 2025 reduction in Wegovy self-pay costs. We hold the exact figure as unverified pending a direct re-check, because the numbers moved several times in late 2025 and our data are only as current as our last verification. What is clear is the direction: the gap between an FDA-approved semaglutide product and compounded semaglutide narrowed sharply.
Compounded injectable semaglutide remains cheaper. NexLife's verified 12-month plan is $119 per month, month-to-month $139, and other providers cluster between $120 and $200. At those prices, the tablet costs more per month than the cheapest compounded injection but less than a year ago's brand prices, and it comes with FDA approval, a measured dose, and a trial.
Who should choose the tablet
Patients who will not inject. This is the group the tablet was made for. Before December 2025, their options were compounded sublingual or ODT products with no absorption data (see the sublingual guide). Now there is an evidence-based oral option.
Patients who want an FDA-approved product. The tablet's identity, dose and quality are verified; a compounded vial's are not.
Patients whose insurance covers it. Coverage of oral Wegovy under employer plans is expanding; a copay may beat any cash price.
Patients with cardiovascular disease. The SELECT cardiovascular benefit was shown with injectable Wegovy; the oral form's cardiovascular outcome data are pending (SOUL showed benefit for oral semaglutide in diabetes). For these patients the injectable remains the evidence-based choice, with the tablet as a reasonable alternative if injection is not acceptable.
Who should choose compounded injectable semaglutide
Cost-constrained cash-pay patients who accept the compounded product's regulatory status and can inject. A $119-$139 compounded plan is the cheapest GLP-1 in our database, and at a flat all-inclusive provider it carries no hidden dose or membership charges.
Patients who cannot keep the dosing ritual. A shift worker, or anyone who cannot reliably take a tablet first thing on an empty stomach and wait 30 minutes, will absorb less than the trial participants did. A weekly injection has no such constraint.
Patients at higher doses. The tablet comes in one maintenance dose; injectable semaglutide's 2.4 mg, and compounded semaglutide's flexibility, allow individualized dosing that the tablet does not.
Practical points before switching to the tablet
The tablet has three practical constraints the injection does not. It must be taken on an empty stomach with no more than a small amount of water and nothing else for about 30 minutes, because the absorption enhancer needs an empty, undiluted stomach; a patient who takes it with breakfast gets a fraction of the dose. Absorption is also variable from day to day for the same reason, so the exposure is less predictable than a weekly injection, which the trials accommodated by using a high nominal dose. And it is a daily habit rather than a weekly one, which some patients prefer and others forget. A patient moving from compounded injectable semaglutide to the tablet should expect a fresh escalation with the usual gastrointestinal effects in the first weeks, should not overlap the two, and should ask the prescriber how the tablet dose corresponds to the injectable dose they had reached, because the correspondence is not one to one. Cost should be checked at the time of switching rather than assumed: the launch price for the lowest tablet dose was set below the injectable pen price, but higher tablet doses and the manufacturer's channel pricing changed during the launch period and are among the figures most likely to be out of date on any comparison site. The semaglutide reference records the current benchmark rows and their verification status.
The comparison in one paragraph
The oral Wegovy tablet delivers about 13.6% weight loss at 64 weeks, is FDA-approved, costs more than the cheapest compounded injections and less than brand pens did a year ago, and requires a strict morning ritual. Compounded injectable semaglutide delivers a similar drug at a lower price without FDA oversight of the product. For a patient who will not inject, the tablet is the only evidence-based option. For a patient who will, the decision is price and regulatory comfort, and the cheapest semaglutide guide and NovoCare benchmark give the numbers to compare.
Frequently asked questions
How much weight do you lose on the oral Wegovy pill?
In OASIS 4, adults with obesity taking oral semaglutide 25 mg daily lost about 13.6% of body weight at 64 weeks versus about 2.2% on placebo. The injectable produced 14.9% at 68 weeks in STEP 1, so the two are close.
How do you take oral Wegovy?
Once daily on an empty stomach, first thing, with up to 4 ounces of plain water, then nothing to eat or drink for 30 minutes. The absorption enhancer needs an empty, undiluted stomach; taking it with food or more water reduces the dose absorbed.
Is oral Wegovy cheaper than compounded semaglutide?
Usually not. Compounded injectable semaglutide is available for $119-$139 per month; the tablet's launch self-pay price was lower than Wegovy pens but, as of our last check, above the cheapest compounded plans. The tablet is FDA-approved; the compounded product is not.
Is oral Wegovy the same as sublingual compounded semaglutide?
No. Oral Wegovy is swallowed and absorbed in the stomach with the SNAC enhancer, with measured bioavailability and a trial program. Compounded sublingual or ODT semaglutide has no absorption data or trial.
Sources
- Wegovy tablets (oral semaglutide 25 mg) prescribing information, December 2025
- Wharton S et al. Oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4). N Engl J Med 2025
- Knop FK et al. OASIS 1, oral semaglutide 50 mg. Lancet 2023;402:705-719
- Rybelsus prescribing information, clinical pharmacology
- Wilding JPH et al. STEP 1. N Engl J Med 2021;384:989-1002
- NovoCare Pharmacy self-pay pricing announcements, 2025 (pending verification)
Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.